6-chloro-3-(3-trifluoromethylbenzylidene)-1,3-dihydroindol-2-one

Compound 47 (6-chloro-3-(3-trifluoromethylbenzylidene)-1,3-dihydroindol-2-one) is an investigational small molecule multi-targeted tyrosine kinase inhibitor (TKI) being developed for the treatment of hepatocellular carcinoma (HCC). Developed through a collaboration between the National University of Singapore, the Singapore OncoGenome Laboratory, and the Institute of Molecular and Cell Biology (A*STAR), it is based on a benzylidene-indolinone scaffold. The compound functions by inhibiting the phosphorylation of several key receptor tyrosine kinases involved in tumor progression, specifically the insulin-like growth factor 1 receptor (IGF-1R), tyrosine-protein kinase receptor TYRO3, and ephrin type-A receptor 2 (EphA2). Preclinical studies have demonstrated that Compound 47 exhibits potent anti-proliferative, anti-migratory, and pro-apoptotic effects in HCC cell lines and suppresses tumor growth in xenograft models. It also reduces the transcription of alpha-fetoprotein (AFP), a clinical marker for HCC, and has demonstrated a favorable safety profile in early-stage research compared to established TKIs like sorafenib.

Other names

E/Z 6-Chloro-3-(3-trifluoromethyl-benzyliden)-1,3-dihydroindol-2-one6-chloro-3-(3-trifluoromethylbenzylidene)indolin-2-one